Related Experiment Video

Updated: Apr 11, 2026

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

22.2K

TAZ promotes temozolomide resistance by upregulating MCL-1 in human glioma cells

Tian Tian1, Aimin Li2, Hong Lu1

  • 1Department of Neurology, The First Affiliated Hospital, Zhengzhou University, Zhengzhou 450052, PR China; Institute of Clinical Medicine, The First Affiliated Hospital, Zhengzhou University, Zhengzhou 450052, PR China.

Biochemical and Biophysical Research Communications
|June 6, 2015
PubMed

Insights

Transcriptional co-activator with PDZ-binding motif (TAZ) promotes temozolomide resistance in glioblastoma multiforme (GBM) by inhibiting apoptosis. Targeting TAZ may improve outcomes for patients with temozolomide-resistant GBM.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Temozolomide is a first-line chemotherapy for glioblastoma multiforme (GBM).
  • Chemoresistance to temozolomide is a major challenge in treating GBM.
  • The mechanisms underlying temozolomide resistance are not fully understood.

Purpose of the Study:

  • To investigate the role of transcriptional co-activator with PDZ-binding motif (TAZ) in temozolomide resistance in glioma cells.
  • To explore the potential of TAZ as a therapeutic target for overcoming temozolomide resistance in GBM.

Main Methods:

  • Correlation analysis of TAZ expression with temozolomide resistance in human glioma cells.
  • Overexpression and knockdown experiments of TAZ in U-87MG and U-251MG cell lines.
  • Analysis of TAZ's effect on temozolomide-induced apoptosis and MCL-1 expression.

Main Results:

  • TAZ expression positively correlated with temozolomide chemoresistance in human glioma cells.
  • TAZ overexpression conferred temozolomide resistance, while TAZ knockdown sensitized cells to temozolomide.
  • TAZ inhibits temozolomide-induced apoptosis by upregulating myeloid cell leukemia 1 (MCL-1).
  • High TAZ expression is associated with a poor prognosis in GBM patients.

Conclusions:

  • TAZ plays a critical role in mediating temozolomide resistance in glioma cells.
  • TAZ represents a promising therapeutic target for improving treatment outcomes in temozolomide-resistant gliomas.
Keywords:
ApoptosisGliomaTAZTemozolomide resistance

More Related Videos

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

3.3K
The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

19.7K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K